Arterial Remodeling Technologies, a Noisy le Roi, France-based developer of bioresorbable coronary polymer stents that are designed to promote the natural remodeling of an injured artery after angioplasty, has closed on a $8.5m new venture financing round.
Investors include existing backers Matignon Technologies and Amundi Private Equity Funds, and new partner InnoBio Fund, which is managed by CDC Entreprises.
This bring the total amount raised by the company to date to $17m.
Arterial’s technology for fully resorbable coronary stents is designed to promote natural remodeling of an injured artery after angioplasty. It is based on intellectual property originating from:
– the Cleveland Clinic;
– CNRS (Centre National de Recherche Scientifique), Montpellier, France;
– Descartes University, Paris.